Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 82Carcinoma, Non-Small-Cell Lung 72Carcinoma, Renal Cell 42Neoplasm Metastasis 31Neoplasms 29Squamous Cell Carcinoma of Head and Neck 26Lung Neoplasms 25Colorectal Neoplasms 23Carcinoma, Hepatocellular 20Hodgkin Disease 18Small Cell Lung Carcinoma 17Prostatic Neoplasms 14Carcinoma, Transitional Cell 13Head and Neck Neoplasms 12Urinary Bladder Neoplasms 11Pancreatic Neoplasms 11Ovarian Neoplasms 11Multiple Myeloma 11Advanced Cancer 11Triple Negative Breast Neoplasms 10Lymphoma 10Glioblastoma 10Kidney Neoplasms 9Breast Neoplasms 9Recurrence 8Lymphoma, Non-Hodgkin 8Leukemia, Myeloid, Acute 8Glioma 8Stomach Neoplasms 7Myelodysplastic Syndromes 7

Interventions

olaparib 1enfortumab vedotin 1Oxaliplatin 1Nivolumab 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Urothelial Cancer × Nivolumab × Clear all
NCT03451331 2024-05-16

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Hoosier Cancer Research Network

Phase 2 Completed
49 enrolled 15 charts
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡